Alnylam Pharmaceuticals' Interest & Investment Income fell 10.78% to $28.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.9 million, marking a year-over-year decrease of 4.55%. This contributed to the annual value of $122.0 million for FY2024, which is 27.66% up from last year.
Per Alnylam Pharmaceuticals' latest filing, its Interest & Investment Income stood at $122.0 million for FY2024, which was up 27.66% from $95.6 million recorded in FY2023.
Alnylam Pharmaceuticals' Interest & Investment Income's 5-year high stood at $122.0 million during FY2024, with a 5-year trough of $1.6 million in FY2021.
Its 3-year average for Interest & Investment Income is $80.8 million, with a median of $95.6 million in 2023.
As far as peak fluctuations go, Alnylam Pharmaceuticals' Interest & Investment Income plummeted by 86.63% in 2021, and later soared by 1,471.12% in 2022.
Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Interest & Investment Income stood at $11.8 million in 2020, then crashed by 86.63% to $1.6 million in 2021, then spiked by 1,471.12% to $24.8 million in 2022, then soared by 285.20% to $95.6 million in 2023, then rose by 27.66% to $122.0 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value